New vaccine aims to train immune system against myeloma
NCT ID NCT02334865
First seen May 15, 2026 · Last updated May 22, 2026 · Updated 3 times
Summary
This early-phase trial tests a vaccine (SVN53-67/M57-KLH) designed to help the immune system recognize and attack multiple myeloma cells. It is given alongside a standard maintenance drug (lenalidomide) to 18 patients who have already responded to initial treatment. The main goals are to check safety and see if the vaccine boosts the body's immune response against cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
University of Rochester Medical Center
Rochester, New York, 14642, United States
Conditions
Explore the condition pages connected to this study.